Search Results - "Diallo, Béré"

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma by Kassem, Sahar, Diallo, Béré K., El-Murr, Nizar, Carrié, Nadège, Tang, Alexandre, Fournier, Alain, Bonnevaux, Hélène, Nicolazzi, Céline, Cuisinier, Marine, Arnould, Isabelle, Sidhu, Sukhvinder S., Corre, Jill, Avet-Loiseau, Hervé, Teillaud, Jean-Luc, van de Velde, Helgi, Wiederschain, Dmitri, Chiron, Marielle, Martinet, Ludovic, Virone-Oddos, Angela

“…Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress…”
Get full text

BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells by Gamain, Benoît, Brousse, Carine, Rainey, Nathan E, Diallo, Béré K, Paquereau, Clara-Eva, Desrames, Alexandra, Ceputyte, Jolita, Semblat, Jean-Philippe, Bertrand, Olivier, Gangnard, Stéphane, Teillaud, Jean-Luc, Chêne, Arnaud

“…Industrial production of therapeutic monoclonal antibodies is mostly performed in eukaryotic-based systems, allowing posttranslational modifications mandatory…”
Get full text

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy by Casadesús, Ana Victoria, Deligne, Claire, Diallo, Béré Kadjdiatou, Sosa, Katya, Josseaume, Nathalie, Mesa, Circe, León, Kalet, Hernández, Tays, Teillaud, Jean-Luc

“…Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or…”
Get full text

Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection by Diallo, Béré K., Ní Chasaide, Caitlín, Wong, Ting Y., Schmitt, Pauline, Lee, Katherine S., Weaver, Kelly, Miller, Olivia, Cooper, Melissa, Jazayeri, Seyed D., Damron, F. Heath, Mills, Kingston H. G.

“…Current COVID-19 vaccines prevent severe disease, but do not induce mucosal immunity or prevent infection with SARS-CoV-2, especially with recent variants…”
Get full text

MAbs: the history of a basic research or the curiosity as a source of wealth by Diallo, Béré K, Riffard, Clémence, Le Gouge, Kenz, Teillaud, Jean-Luc

“…In 2019, monoclonal antibodies are a worldwide annual business worth of more than 100 billions USD (i.e., about 90 billions €). In addition to their use in the…”
Get more information

Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma by Virone-Oddos, Angela, Kassem, Sahar, Diallo, Béré, Tang, Alexandre, Fournier, Alain, El-Murr, Nizar, Carrie-Constantin, Nadege, Nicolazzi, Céline, Arnould, Isabelle, Avet-Loiseau, Hervé, Sidhu, Sukhvinder S., Martinet, Ludovic, Chiron, Marielle

“…Abstract CD38 is a cell surface glycoprotein highly expressed in multiple myeloma (MM) cells making it an attractive target for antibody–based therapy…”
Get full text

Selumetinib-based therapy in uveal melanoma patient-derived xenografts by Decaudin, Didier, El Botty, Rania, Diallo, Béré, Massonnet, Gerald, Fleury, Justine, Naguez, Adnan, Raymondie, Chloé, Davies, Emma, Smith, Aaron, Wilson, Joanne, Howes, Colin, Smith, Paul D, Cassoux, Nathalie, Piperno-Neumann, Sophie, Roman-Roman, Sergio, Némati, Fariba

“…The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the…”
Get full text

Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts by Decaudin, Didier, Botty, Rania EL, Diallo, Béré, Massonnet, Gerald, Fleury, Justine, Naguez, Adnan, Dubois, Marine, Davies, Emma J., Smith, Aaron, Wilson, Joanne, Howes, Colin, Smith, Paul, Cassoux, Nathalie, Mariani, Pascale, Piperno-Neumann, Sophie, Roman, Sergio Roman, Nemati, Fariba

“…Abstract Purpose: The prognosis of metastatic uveal melanoma (UM) patients remains one of the worst observed in human cancers. The identification of frequently…”
Get full text

Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma by Diallo, Béré, Massonnet, Gerald, El-Botty, Rania, Raymondie, Chloé, Carita, Guillaume, Roman-Roman, Sergio, Smith, Paul, Davies, Emma, Decaudin, Didier, Némati, Fariba

“…Abstract Uveal melanomas (UM) constitute the most common primary intraocular tumors in adults and are characterized by a constitutive activation of the MAPK…”
Get full text